Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.

British journal of haematology - 1 Jan 2013

Nielsen Camilla, Birgens Henrik S, Nordestgaard Børge G, Bojesen Stig E

Abstract excerpt

The JAK2 V617F somatic mutation is present in the majority of patients with myeloproliferative cancer (polycythaemia vera, essential thrombocytosis, and primary myelofibrosis). However, the diagnostic value of the JAK2 V617F somatic mutation for myeloproliferative cancer in the general population...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Neoplasms
Share to Genotype
Share to Incidence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Survival Analysis

Share to Young Adult

Source

Identifiers

PMID: 23116358
DOI: 10.1111/bjh.12099

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23116358-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.PMID 23116358Read ↗

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.Semantic proximity Read ↗

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.Semantic proximity Read ↗

Myeloproliferative neoplasms and JAK2 mutations.Semantic proximity Read ↗

The presence of the <i>JAK2</i> V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemiaSemantic proximity Read ↗

Association between JAK2V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasmsSemantic proximity Read ↗

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burdenSemantic proximity Read ↗

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.Semantic proximity Read ↗

<i>JAK2</i><sup>V617F</sup> mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevanceSemantic proximity Read ↗

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.Semantic proximity Read ↗

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.